

1. General Information

| | |
|-------------------------------|--|
| Cohort ID | 5020_21 |
| Title (Study Name) | The CoVVacBoost Study |
| Principal investigator | Assoc. Prof. Martin Stradner, Prof. Ivo Steinmetz |
| Contact information | pm-biobank@medunigraz.at |
| Funding agency | ---- |

2. Description

The aim of this study is to evaluate the ability of a COVID-19 booster vaccine to induce a salivary antibody response and to investigate a possible correlation with the serum antibody response and the cellular response. A quantitative and functional comparison of the salivary anti-SARS-CoV-2 antibody response before and after 3rd booster vaccination will be investigated. Volunteers, who get their 3rd vaccination at the "Impfstraße" at the LKH-Univ. Klinikum Graz are asked to participate in this study. Blood and saliva samples will be obtained during 3 visits.

Visit 1 (before the 3rd booster vaccination): Serology, PBMCs, saliva

Visit 2 (3 – 8 weeks after the 3rd booster vaccination): Serology, PBMCs, saliva

Visit 3: 6 months after the 3rd booster vaccination: Serology, saliva

The following data are collected for all participants: type of COVID-19 vaccinations, medical history (including immunosuppressive therapies, chronic graft versus host disease, severe opportunistic infections, prior vaccination history (types, titers if available), current and past disease including COVID-19), current medication, BMI, smoking habits.

3. Details

| | | |
|--|---|--|
| ICD 10/O codes / Healthy | healthy | |
| Key words | vaccination, COVID-19, SARS-CoV-2, mRNA vaccine, booster, 3 rd dose, Moderna, Comirnaty, AstraZeneca | |
| Collection / Cohort size 12/2022 | 1.571 serum, 370 saliva and 606 PBMC aliquots from 140 patients | |
| Informed Consent (IC) | <input checked="" type="checkbox"/> Broad Biobank IC <input checked="" type="checkbox"/> Specific Study IC | |
| Status | <input checked="" type="checkbox"/> In progress / compl. date: 01/2023 <input type="checkbox"/> Completed | |
| Inclusion criteria | Age distribution | 18+ |
| | Sex distribution (f:m) | ~50:50 |
| | Others | <ul style="list-style-type: none"> • second dose AstraZeneca plus third dosis Moderna • second dose AstraZeneca plus third dosis Comirnaty • second dose Moderna plus third dosis Moderna • second dose Comirnaty plus third dosis Comirnaty |
| Earliest access | As of now | |

| | | | |
|---|--|--|--|
| Quality-standards | <input checked="" type="checkbox"/> ISO 9001:2015 (SOPs) | | |
| Associated publications / references | ----- | | |

4. Material available (aliquot size) and storage conditions

| | | | |
|-----------------|--|---|---|
| Material | <input checked="" type="checkbox"/> Serum (580 µl) | <input checked="" type="checkbox"/> -80°C | <input type="checkbox"/> liq. N ₂ |
| | <input checked="" type="checkbox"/> PBMC's | <input checked="" type="checkbox"/> -80°C | <input checked="" type="checkbox"/> liq. N ₂ |
| | <input checked="" type="checkbox"/> Saliva | <input checked="" type="checkbox"/> -80°C | <input type="checkbox"/> liq. N ₂ |

| | |
|--|--|
| Dokument erstellt (tt/mm/yyyy): 22/12/2021 | Letzte inhaltliche Aktualisierung (tt/mm/yyyy): 09/08/2023 |
|--|--|